Elotuzumab plus lenalidomide and dexamethasone in relapsed/refractory multiple myeloma: Extended 3‐year follow‐up of a multicenter, retrospective clinical experience with 319 cases outside of controlled clinical trials

Bruzzese, Antonella, Derudas, Daniele, Galli, Monica · Hematological Oncology · 2022